Charles River Laboratories Intl. Inc vs Lithium Americas Corp — how do they compare? Charles River Laboratories Intl. Inc trades at $281.43 (market cap $13.46B), while Lithium Americas Corp trades at $3.27 (market cap $1.18B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 11.4× Lithium Americas Corp's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Lithium Americas Corp nearer its low. Which is the better fit depends on your goals.
| CRL | LAC | |
|---|---|---|
Market Cap | $13.46B | $1.18B |
Sector | Health | Basic Materials |
52-Week High | $282.00 | $10.05 |
52-Week Low | $145.57 | $2.71 |
Enterprise Value | $16.30B | $1.29B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.
While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.
Lithium Americas (LAC) trades at $3.25 with mixed technical signals showing a bullish overall trend but neutral oscillators. The company reported negative profitability metrics with ROE at -11.35% and net income of -$122.09M for 2025, though it secured $175M financing for Thacker Pass construction. Recent earnings show volatility with two beats and one miss in the last four quarters.
LAC faces significant execution risks with substantial capital expenditures needed, but analyst sentiment remains positive with 7 buy ratings and no sell recommendations. The stock's valuation at 0.88 P/B suggests potential upside if lithium demand recovers, though negative cash flow from operations and high investing outflows present near-term challenges.
Trailing returns across standard periods
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →